Incretin Mimetics: How They Work and Their Uses

Incretin mimetics are a class of drugs that copy the action of gut hormones called incretins, which your body naturally releases after eating to help regulate blood sugar. The most familiar members are the GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), though newer drugs now target more than one incretin pathway at once. Originally developed for type 2 diabetes, these medications have rapidly expanded into treatments for obesity, cardiovascular risk reduction, and a growing list of other conditions, largely because the incretin system touches so many organs and tissues beyond the pancreas.

The Incretin System They Imitate

When you eat, cells lining your small intestine release two key hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both hormones travel through the bloodstream to the pancreas, where they nudge beta cells to release insulin in proportion to how much glucose is circulating. This glucose-dependence is crucial: the hormones boost insulin only when blood sugar is elevated, which is why incretin-based drugs carry a low intrinsic risk of causing dangerously low blood sugar. The natural versions of GLP-1 and GIP are broken down within minutes by an enzyme called dipeptidyl peptidase IV (DPP-IV), so their window of activity is short.¹ Incretin mimetics are engineered to resist that breakdown, staying active in the body for hours or even days rather than minutes.

GLP-1 and GIP do more than stimulate insulin. GLP-1 also suppresses glucagon, the hormone that tells the liver to dump sugar into the blood, which further helps lower blood glucose during and after meals. GIP, interestingly, behaves differently depending on the metabolic context: it can actually raise glucagon during low blood sugar, acting as a safeguard against hypoglycemia. The two hormones also have opposing roles in fat tissue. GLP-1 indirectly promotes fat breakdown, while GIP directly supports the creation of new fat cells in appropriate locations, and together they help maintain healthy fat distribution and boost production of adiponectin, a hormone associated with insulin sensitivity.²

How Incretin Mimetics Work at the Cellular Level

The primary target of GLP-1 receptor agonists is the GLP-1 receptor on pancreatic beta cells. When the drug binds this receptor, it amplifies the same signaling cascades that natural GLP-1 triggers, but more intensely and for longer. The result is a potent boost to glucose-stimulated insulin secretion. The glucose-dependence is built into the biology: the receptor can amplify insulin release when blood sugar is high, but has little effect when glucose is normal or low.³ This is a meaningful safety advantage over older insulin-stimulating drugs like sulfonylureas, which push insulin release regardless of glucose levels and can cause hypoglycemia.

Beyond the pancreas, GLP-1 receptors sit on cells throughout the body, including the stomach, heart, kidneys, and brain. In the stomach, activating these receptors slows gastric emptying, meaning food moves more slowly from the stomach into the intestine.⁴ This contributes to feeling full longer after a meal and blunts the post-meal glucose spike. It also helps explain some of the gastrointestinal side effects people experience on these drugs.

Effects on the Brain, Appetite, and “Food Noise”

GLP-1 receptors have been found in several brain regions involved in hunger and reward processing, including the hypothalamus, the medulla, and the parietal cortex. A crossover trial using brain imaging showed that liraglutide decreased activation in the parietal cortex when people with diabetes viewed images of highly desirable foods, and secondary analyses found decreased activation in the insula and putamen, areas tied to the brain’s reward circuitry.⁵ In that same study, increased ratings of hunger correlated with increased brain activation in response to desirable food cues while on liraglutide, suggesting the drug does not simply override appetite but modulates how the brain evaluates food-related signals.

This brain-level effect is what many patients describe as the quieting of “food noise,” the persistent, intrusive thoughts about food that can dominate the mental life of someone living with obesity. Neuroimaging and behavioral data suggest that GLP-1-based drugs may influence the neural systems underlying cue salience and reward anticipation, with multiple reports of reduced food-related intrusive thoughts.⁶ The subjective experience people describe, feeling freed from constant preoccupation with eating, appears to have a real neurological basis, though the research is still early-stage and much of the mechanistic detail remains to be worked out.

Blood Sugar Control

GLP-1 receptor agonists are now recommended as the preferred first injectable therapy for type 2 diabetes, ahead of insulin, because they offer comparable or superior blood sugar lowering while also reducing weight and carrying a low risk of hypoglycemia.⁷ Among the available agents, long-acting formulations like once-weekly semaglutide produce the most pronounced effects on fasting glucose and HbA1c. A large network meta-analysis comparing 15 GLP-1 receptor agonists found that tirzepatide, which activates both GIP and GLP-1 receptors, produced the largest reductions in HbA1c and fasting glucose of any drug in the class.⁸

Weight Loss and Body Composition

Weight reduction is one of the most visible effects of incretin mimetics. A systematic review and meta-analysis of GLP-1 receptor agonists in adults with overweight or obesity found that body weight decreased by roughly 9% at three months, around 5% at six months, and about 4% at twelve months, with fat mass accounting for the majority of the loss and lean mass remaining largely preserved.⁹ The concern that these drugs cause excessive muscle loss has received considerable attention, but the picture is more nuanced than the headlines suggest.

A study comparing body composition changes between bariatric surgery and GLP-1 receptor agonists found that at two years, the GLP-1 group had an average fat mass reduction of about 18% and a fat-free mass reduction of roughly 3%, while surgery produced much larger changes in both compartments. The ratio of fat-free mass to fat mass actually improved in both groups, meaning the proportion of body weight that is lean tissue increased.¹⁰ A separate review found wide variation across studies, with some reporting that lean mass losses made up 40–60% of total weight lost, while others showed lean mass reductions of about 15% or less. The authors noted that when assessed with MRI, skeletal muscle changes appeared adaptive, meaning they were proportional to what you would expect given the degree of weight loss, and that improved insulin sensitivity and reduced fat infiltration into muscle tissue may actually improve muscle quality even as volume decreases.¹¹ Resistance training during treatment remains the most practical strategy for anyone concerned about preserving strength.

Cardiovascular and Kidney Benefits

The cardiovascular benefits of GLP-1 receptor agonists now stand on strong footing. A meta-analysis pooling data from nearly 100,000 patients found high-certainty evidence that these drugs reduced all-cause death by about 12%, cardiovascular death by roughly 13%, and major adverse cardiovascular events by about 13% compared with controls. They also lowered the risk of heart attack by around 15%, heart failure hospitalization by about 15%, and acute kidney failure by roughly 9%.¹² These benefits were not evenly distributed across all patients, however. A study examining outcomes by body mass index found that in people with type 2 diabetes who had a BMI of 25 or above, GLP-1 receptor agonists significantly reduced MACE and cardiovascular death compared to DPP-4 inhibitors. In those with a normal BMI (under 25), the cardiovascular benefit was not statistically significant.¹³

On the kidney side, a systematic review and meta-analysis found that GLP-1 receptor agonists reduced composite renal outcomes by about 19%, slowed the annual decline in kidney filtration rate, and cut the risk of developing microalbuminuria (an early sign of kidney damage) by roughly a quarter. They did not, however, significantly reduce progression to outright kidney failure.¹⁴ The kidney findings are encouraging, especially for people with diabetes who are at elevated risk of chronic kidney disease, but they suggest the drugs are better at protecting kidney function early than rescuing it once serious damage has set in.

Liver Disease

Metabolic-associated steatotic liver disease (formerly called non-alcoholic fatty liver disease) is common in people with obesity and type 2 diabetes, and there are few effective drug treatments. GLP-1 receptor agonists are showing real promise here. A meta-analysis found that GLP-1 agonists tripled the rate of resolution of metabolic-associated steatohepatitis (the inflammatory stage of liver disease) without worsening fibrosis, and also improved fibrosis by about 45% without worsening steatohepatitis, compared to controls.¹⁵ A separate systematic review found that GLP-1 receptor agonist treatment for a median of 24 weeks significantly reduced liver fat content, improved steatosis, hepatocellular ballooning, and lobular inflammation on biopsy, though the evidence was stronger for some agents than others.¹⁶ For a condition that has long lacked pharmacological options, these results are generating real clinical excitement.

Dual and Triple Receptor Agonists

The first generation of incretin mimetics targeted only GLP-1 receptors. The field has now moved toward drugs that activate multiple incretin and related hormone receptors simultaneously. Tirzepatide (Mounjaro, Zepbound) is the first approved dual GIP/GLP-1 receptor agonist, engineered as a single molecule that activates both receptors.¹⁷ In clinical trials, it proved superior to single GLP-1 receptor agonists for blood sugar control.¹⁸

Further along the pipeline is retatrutide, a triple agonist that activates the GLP-1, GIP, and glucagon receptors. A phase 2 trial reported that participants receiving the highest dose of retatrutide achieved roughly 24% body weight loss at 48 weeks, a figure that approaches what bariatric surgery delivers.¹⁹ Adding glucagon receptor activity may seem counterintuitive since glucagon raises blood sugar, but glucagon also boosts energy expenditure and fat oxidation. The trick is balancing the glucose-raising effect of glucagon with the glucose-lowering power of GLP-1 and GIP stimulation, and early data suggest the formula works. Phase 3 trials are underway.

Side Effects and Safety Concerns

Gastrointestinal complaints are by far the most common side effects of incretin mimetics. Nausea, vomiting, diarrhea, and constipation occur frequently, especially during the initial dose-escalation period, and are the leading reason people discontinue treatment. The large cardiovascular meta-analysis of nearly 100,000 patients found that GLP-1 receptor agonists increased gastrointestinal disorders by about 63% and gallbladder disorders by roughly 26% compared to controls.¹²

More serious but less common gastrointestinal events are also on the radar. A study comparing GLP-1 agonists used for weight loss against bupropion-naltrexone found elevated risks of pancreatitis, bowel obstruction, and gastroparesis with the GLP-1 drugs.²⁰ A large cohort study comparing GLP-1-based therapies to SGLT-2 inhibitors (another diabetes drug class) found the GLP-1 group had a higher rate of severe gastrointestinal motility events, with a rate difference of about 0.27 per 100 person-years.²¹ In absolute terms these events are rare, but they are worth knowing about, especially for people with a history of gastrointestinal problems.

The question of whether incretin mimetics raise the risk of pancreatitis or thyroid cancer has lingered since the early days of the class. Early adverse-event analyses from the FDA reporting system found elevated reporting rates for pancreatitis with exenatide and sitagliptin.²² However, those databases suffer from well-known reporting biases, and subsequent clinical trials and post-marketing analyses have not confirmed a significant link between GLP-1 receptor agonist use and pancreatitis or cancer.²³ The animal-model concern about thyroid C-cell tumors led to a boxed warning in the US, though this finding has not been replicated in humans. The practical takeaway is that the risk, if it exists, appears small at the population level, but anyone with a personal or family history of medullary thyroid cancer should avoid these drugs.

What Happens When You Stop

Weight regain after discontinuation is one of the most important practical realities of incretin mimetic therapy. These drugs do not cure obesity; they manage it, and stopping treatment reliably leads to weight rebound. A meta-analysis found that on average, people regained about 4 kg after stopping, along with increases in BMI, waist circumference, and HbA1c, though some statistically significant weight loss relative to their pre-treatment baseline persisted.²⁴ Another meta-analysis found that the weight rebound was significantly higher after discontinuing tirzepatide than after stopping semaglutide, likely reflecting the fact that tirzepatide produces larger weight losses to begin with.²⁵

The clinical implication is straightforward: for sustained benefits, most people will need to continue treatment indefinitely, much as you would with blood pressure medication. This is not a failure of the drugs so much as a reflection of how obesity works biologically. The body defends its higher weight set point through hormonal and neural mechanisms that do not resolve simply because you lost weight on a medication. That reality also makes cost and access issues harder to ignore.

Cost and Access

Despite their effectiveness, incretin mimetics are expensive, and that expense creates real barriers. At current US pricing, GLP-1 receptor agonists rarely meet standard cost-effectiveness thresholds, even though over a full lifetime the cost per quality-adjusted life year may eventually look reasonable.²⁶ The massive size of the population that could benefit, combined with the likelihood of long-term or lifelong use, creates a cost challenge that no individual patient’s insurance plan was designed for.²⁷ Medicare currently does not cover anti-obesity medications for weight loss (as distinct from diabetes treatment), and many private insurers impose strict prior authorization requirements. Compounding pharmacies have filled part of the gap with lower-cost formulations, though questions about quality control and dosing consistency remain active. The entry of oral formulations and new competitors into the market may eventually drive prices down, but for now, affordability is a genuine obstacle for many people who would benefit.

Oral Formulations and the Move Away From Injections

Most incretin mimetics on the market require weekly subcutaneous injections, which is a barrier for some patients. The first oral GLP-1 receptor agonist, oral semaglutide (Rybelsus), was developed by co-formulating semaglutide with a permeation enhancer that protects the peptide from stomach acid and helps it cross the gut lining into the bloodstream.²⁸ Oral semaglutide needs to be taken on an empty stomach with a small amount of water, and you have to wait at least 30 minutes before eating, drinking, or taking other medications, because food and fluid interfere with absorption.

An even bigger step is orforglipron, a non-peptide GLP-1 receptor agonist currently in clinical trials. Unlike semaglutide, which is a modified version of the natural peptide, orforglipron is a small molecule designed from scratch to activate the same receptor. Being a small molecule rather than a peptide makes it inherently easier to formulate as a daily pill without the absorption challenges that peptides face in the gut.²⁹ If approved, it could substantially simplify treatment and potentially reduce manufacturing costs.

Use in Children and Adolescents

Pediatric obesity has risen sharply, and the extension of incretin mimetics to younger populations is already underway. A meta-analysis of GLP-1 receptor agonists in children and adolescents with obesity or type 2 diabetes found significant reductions in HbA1c, fasting glucose, body weight, and BMI. Gastrointestinal side effects were more common in treated groups, consistent with the adult profile, but there was no significant increase in suicidal ideation or behaviors.³⁰ That said, long-term safety data in adolescents remain limited, with only one large randomized trial of semaglutide in youth completed as of mid-2024, and follow-up of just 68 weeks.³¹ Questions about effects on growth, bone density, and the psychological dimensions of long-term pharmacological weight management in adolescents are still unanswered. The short-term results are encouraging, but prescribing these drugs to a teenager involves a different risk calculus than prescribing them to a 55-year-old with established cardiovascular disease.

Neuroprotection and Other Emerging Research

Some of the most intriguing early-stage research involves the brain. GLP-1 receptors are widely distributed in the central nervous system, and researchers have begun testing whether incretin mimetics could slow neurodegeneration. In animal models of Alzheimer’s and Parkinson’s disease, dual GLP-1/GIP receptor agonists have shown neuroprotective effects, including reduced inflammation, decreased oxidative stress, preserved synaptic function, and protection of dopaminergic neurons. Newer dual analogues engineered to cross the blood-brain barrier showed effects that were superior to those of single GLP-1 analogues alone.³² These are animal studies, and the leap from rodent models to human neurodegenerative disease is notoriously large. But clinical trials are now underway in humans, and the fact that millions of people are already taking these drugs for metabolic conditions creates a natural observational dataset that epidemiologists are actively mining for signals.

The Lizard Connection

The origin story of incretin mimetics has an improbable character: the Gila monster. Exenatide, the first GLP-1 receptor agonist approved for clinical use, was derived from exendin-4, a peptide found in the saliva of the venomous lizard Heloderma suspectum. Exendin-4 activates the human GLP-1 receptor but resists degradation by DPP-IV far better than the body’s own GLP-1, making it a natural template for drug development. Genomic studies later revealed that genes related to the exendins are not unique to Gila monsters but have ancient origins early in vertebrate evolution, with related sequences found across diverse species. The exendin gene family appears most closely related to the proglucagon and GIP gene families, suggesting deep evolutionary connections among the incretin signaling pathways.³³ Mammals, ironically, lost the exendin gene somewhere along their evolutionary lineage, even as they retained the GLP-1 and GIP systems it is related to.³⁴ The fact that a lizard venom peptide turned out to be the key that unlocked a major class of human therapeutics is one of the better arguments for preserving biodiversity as a pharmaceutical resource.